Agreement Gives Human Longevity Inc. Access to Major Database

San Diego-based Human Longevity Inc., a biological data-driven human health technology and cell therapy company, announced a collaborative agreement with Kings College London to access its TwinsUK Registry.

HLI will conduct whole genome and microbiome sequencing on up to 2,000 individuals, along with metabolomic analysis on up to 6,000 longitudinal samples in TwinsUK, according to Human Longevity.

HLI says it is currently sequencing and analyzing 2,000 genomes per month using Illuminas HiSeq X Ten sequencing machines. The comprehensive data will continue to enrich the HLI Database and HLI Knowledge Base, which includes the companys proprietary informatics analysis and data interpretation and integration. The Database and Knowledge Base form the core of Human Longevitys business. The company is pursuing agreements with a variety of customers including pharmaceutical and biotech companies, academic health systems, governments and insurers.

The TwinsUK Registry is one of the largest and best characterized databases of individuals in the world, said J. Craig Venter, HLIs co-founder, chairman, and chief executive officer. Having access to the clinical phenotype information collectedwill greatly enhance our Database and Knowledge Base, and will enable the teams to collaborate on identifying correlations between phenotypes and genetic predisposition to disease and health.

In July, the company announced that it had recruited Franz Och, scientist and former head of Google Translate, as the companys chief data scientist.

According to HLI, it is building a comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging-related disease and human biological decline.

Human Longevity Inc. is a privately held company founded in 2013.

See more here:
Agreement Gives Human Longevity Inc. Access to Major Database